Central Admixture Pharmacy Services Announces Sale of 503B Product Portfolio to Quva Pharma

Positive

AI Analysis

Summary

QuVa Pharma acquired a portfolio of 503B products from Central Admixture Pharmacy Services to maintain supply of critical medications to U.S. hospitals. The transaction represents a portfolio acquisition in the specialized pharmaceutical services sector.

Outcome Details

Quva Pharma acquired a portfolio of 503B products from Central Admixture Pharmacy Services

Importance:3/10

Sentiment:

0.50

M&A503B pharmacyhospital medicationsproduct portfolio

Read the original article

Published by PR Newswire Pharma on September 8, 2026 5:07 PM

Read Original